Page last updated: 2024-08-21

indazoles and Uveal Neoplasms

indazoles has been researched along with Uveal Neoplasms in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Broom, RJ; Hadden, P; Jebb, A	1
Amirouchene-Angelozzi, N; Carita, G; Dahmani, A; Decaudin, D; Frisch-Dit-Leitz, E; Gentien, D; Liot, G; Némati, F; Raymondie, C; Roman-Roman, S; Schoumacher, M	1

Other Studies

2 other study(ies) available for indazoles and Uveal Neoplasms

Article	Year
Uveal metastasis and myasthenia gravis in a patient with recurrent renal cell carcinoma treated with pazopanib. Clinical genitourinary cancer, 2014, Volume: 12, Issue:4 Topics: Adult; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Male; Myasthenia Gravis; Neoplasm Recurrence, Local; Prognosis; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Uveal Neoplasms	2014
The mTOR inhibitor Everolimus synergizes with the PI3K inhibitor GDC0941 to enhance anti-tumor efficacy in uveal melanoma. Oncotarget, 2016, Apr-26, Volume: 7, Issue:17 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Cycle; Cell Proliferation; Drug Synergism; Everolimus; Humans; Indazoles; Melanoma; Mice; Mice, SCID; Phosphoinositide-3 Kinase Inhibitors; Signal Transduction; Sulfonamides; TOR Serine-Threonine Kinases; Tumor Cells, Cultured; Uveal Neoplasms; Xenograft Model Antitumor Assays	2016

Article

Year

Uveal metastasis and myasthenia gravis in a patient with recurrent renal cell carcinoma treated with pazopanib.

Clinical genitourinary cancer, 2014, Volume: 12, Issue:4

Topics: Adult; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Male; Myasthenia Gravis; Neoplasm Recurrence, Local; Prognosis; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Uveal Neoplasms

2014

The mTOR inhibitor Everolimus synergizes with the PI3K inhibitor GDC0941 to enhance anti-tumor efficacy in uveal melanoma.

Oncotarget, 2016, Apr-26, Volume: 7, Issue:17

Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Cycle; Cell Proliferation; Drug Synergism; Everolimus; Humans; Indazoles; Melanoma; Mice; Mice, SCID; Phosphoinositide-3 Kinase Inhibitors; Signal Transduction; Sulfonamides; TOR Serine-Threonine Kinases; Tumor Cells, Cultured; Uveal Neoplasms; Xenograft Model Antitumor Assays

2016